Routine Screening for Transgender and Gender Diverse Adults Taking Gender-Affirming Hormone Therapy: a Narrative Review

被引:0
|
作者
Sean J. Iwamoto
Frances Grimstad
Michael S. Irwig
Micol S. Rothman
机构
[1] University of Colorado,Division of Endocrinology, Metabolism & Diabetes, Department of Medicine
[2] Anschutz Medical Campus,Department of Endocrinology, Medicine Service
[3] Rocky Mountain Regional Veterans Affairs Medical Center,Division of Gynecology, Department of Surgery
[4] VA Eastern Colorado Health Care System,Division of Endocrinology
[5] UCHealth Integrated Transgender Program,undefined
[6] Boston Children’s Hospital,undefined
[7] Beth Israel Deaconess Medical Center,undefined
[8] Harvard Medical School,undefined
来源
关键词
transgender; screening; cardiovascular disease; osteoporosis; cancer;
D O I
暂无
中图分类号
学科分类号
摘要
Despite the growing number of adult transgender and gender diverse (TGD) patients seeking health services, there are many unknowns regarding how routine screening recommendations should be applied to TGD persons receiving gender-affirming hormone therapy (GAHT). Patients taking GAHT may have disease risks that differ from what is expected based on their sex assigned at birth or affirmed gender identity. We discuss two patient cases, one transgender man and one transgender woman who present for routine medical care, to review several conditions that may be impacted by the hormones utilized in masculinizing and feminizing GAHT and for which screening recommendations are available for TGD adults: cardiovascular risk factors, osteoporosis, breast cancer, cervical cancer, and prostate cancer. We reviewed the TGD-specific screening recommendations from several major medical organizations and programs and found them to be largely based upon expert opinion due to a lack of evidence. The goal of this narrative review is to assist healthcare professionals in counseling and screening their TGD patients when and where appropriate. Not all TGD adults have the ability or need to receive routine medical care from a specialized TGD health clinic; therefore, it is essential for all healthcare professionals involved in routine and gender-affirming care to have knowledge about these conditions and screenings.
引用
收藏
页码:1380 / 1389
页数:9
相关论文
共 50 条
  • [31] Differences Between Transgender and Gender Diverse Adults in Michigan Currently Using Gender-Affirming Hormone Therapy and Nonusers Reporting Interest in Future Use
    Shires, Deirdre A.
    Kattari, Leonardo
    Hill, Haley
    Anderson, Kaston D.
    Misiolek, Brayden
    Kattari, Shanna K.
    [J]. LGBT HEALTH, 2024, 11 (06) : 446 - 454
  • [32] The return of spermatogenesis in transgender women ceasing gender-affirming hormone therapy
    Yau, Mabel
    Safer, Joshua D.
    [J]. CELL REPORTS MEDICINE, 2023, 4 (01)
  • [33] Laboratory Changes During Gender-Affirming Hormone Therapy in Transgender Adolescents
    Millington, Kate
    Lee, Janet Y.
    Olson-Kennedy, Johanna
    Garofalo, Robert
    Rosenthal, Stephen M.
    Chan, Yee-Ming
    [J]. PEDIATRICS, 2024, 153 (05)
  • [34] Gallbladder disease in transgender individuals: associations with gender-affirming hormone therapy
    Tabernacki, Tomasz
    Loria, Matthew
    Rhodes, Stephen
    Pope, Rachel
    Gupta, Shubham
    Banik, Swagata
    Mishra, Kirtishri
    [J]. INTERNATIONAL JOURNAL OF TRANSGENDER HEALTH, 2023,
  • [35] Gender-affirming Hormone Therapy and Risk of Diabetes in Transgender Persons Comment
    Tangpricha, Vin
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (06): : E2632 - E2633
  • [36] Blood pressure changes with gender-affirming hormone therapy in transgender people
    Michihiro Satoh
    [J]. Hypertension Research, 2023, 46 : 792 - 793
  • [37] Thrombosis Risk in Transgender Adolescents Receiving Gender-Affirming Hormone Therapy
    Mullins, Eric S.
    Geer, Rebecca
    Metcalf, Megan
    Piccola, Jeanne
    Lane, Adam
    Conard, Lee Ann E.
    Mullins, Tanya L. Kowalczyk
    [J]. PEDIATRICS, 2021, 147 (04)
  • [38] Blood pressure changes with gender-affirming hormone therapy in transgender people
    Satoh, Michihiro
    [J]. HYPERTENSION RESEARCH, 2023, 46 (03) : 792 - 793
  • [39] The Effect of Gender-Affirming Hormone Therapy on Serum Creatinine in Transgender Individuals
    Maheshwari, Arvind
    Dines, Virginia
    Saul, Dominik
    Nippoldt, Todd
    Kattah, Andrea
    Davidge-Pitts, Caroline
    [J]. ENDOCRINE PRACTICE, 2022, 28 (01) : 52 - 57
  • [40] Metabolic consequences of gender-affirming hormone therapy in transgender adult persons
    Vloemans, Nadia
    Al-Mrayat, Ma'en
    [J]. PRACTICAL DIABETES, 2023, 40 (03) : 12 - 15